Enalaprilat anhydrous
As of the edition of 20 October 2026, Enalaprilat anhydrous is a small molecule: marketed, first approved in 1988 (US); acts on ACE; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1988
- Kind
- Small molecule
- Brand name
- Vasotec
- First approved
- 9 February 1988 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Bausch Health
- Registered trials
- 4, 1 stopped early
- Disease areas
- Heart and blood vessels; Hormones; Inherited and neonatal; Nervous system; Nutrition and metabolism; Skin and connective tissue
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Enalaprilat anhydrous.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ACE | Angiotensin-converting enzyme | P12821 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 3 | 2 | 1 | 0 | 1 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 4 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Merck & Co. | Earlier holder | 1988 to now |
| Bausch Health | Acquired holder | 2005 to now |